Cartesian Therapeutics, Inc. Cash And Cash Equivalents At Carrying Value

Quick Answer

Cartesian Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $125.14 million for the year ending 2025.

  • Cartesian Therapeutics, Inc. showed a decrease of -41.1% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
  • This data is from Cartesian Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
  • XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 13 years of available data (2013 to 2025), Cartesian Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 1,453.2%.
  • Historical annual values: Fiscal year 2025: $125.14 million | Fiscal year 2024: $212.61 million | Fiscal year 2023: $76.91 million | Fiscal year 2022: $106.44 million | Fiscal year 2021: $114.06 million | Fiscal year 2020: $138.69 million | Fiscal year 2019: $89.89 million | Fiscal year 2018: $37.40 million | Fiscal year 2017: $70.62 million | Fiscal year 2016: $58.66 million | Fiscal year 2015: $32.34 million | Fiscal year 2014: $16.59 million | Fiscal year 2013: $8.06 million.
  • Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: